Skip to content
MarketNewsAPI
Live news Screener Coverage Pricing Docs REST API WebSocket API MCP server Company Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
TBRIF$0.030.00(0.00%)Therma Bright Announces up to $420,000 Non-Brokered Private Placement[8:37:00 PM ET]GENNQ$0.000.00(0.00%)Genesis Healthcare Announces Effective Date of Chapter 11 Plan Following Consummation of Sale to West State Street[8:37:00 PM ET]DNRSF$0.36+0.01(+1.42%)DENARIUS METALS FILES TORAL PROJECT TECHNICAL REPORT ON SEDAR+ Denarius Metals Corp. (Cboe CA: DMET) (OTCQX: DNRSF) ("Denarius Metals" or "the Company") announced today the filing of a National Instrument 43-101...[8:36:00 PM ET]RXST$5.02-0.06(-1.18%)RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules[8:00:00 PM ET]TBBK$50.86-0.28(-0.55%)US Metro Bancorp Announces Third Quarter 2026 Results[7:59:00 PM ET]TZOO$5.07-0.02(-0.39%)Club Offers for Travel Enthusiasts in Canada Travelzoo® (NASDAQ: TZOO), the club for travel enthusiasts, announces three of many new Club Offers for Club Members in Canada. Rigorously vetted and ...[7:08:00 PM ET]MRZLF$0.23+0.02(+10.48%)Mirasol Resources Announces Option Grants[6:49:09 PM ET]PGZ$8.71-0.03(-0.34%)Principal Real Estate Income Fund Announces Changes in Portfolio Management[6:45:00 PM ET]CWLPF$0.76+0.02(+2.70%)Caldwell Announces Sale of IQTalent[6:25:00 PM ET]BRCB$9.81+0.16(+1.66%)Black Rock Coffee Bar Continues Expansion in California with New Rancho Cucamonga Location[6:17:23 PM ET]PONIF$0.12-0.00(-3.70%)Silver Pony Announces Closing of Up-Sized $1,600,015 Strategic Unit Offering[6:15:00 PM ET]

UNCY · NASDAQ

Unicycive Therapeutics, Inc.

$3.88 +0.07 (+1.94%)

Company overview

Unicycive Therapeutics, Inc. is a biotechnology company that develops novel therapies for kidney diseases in the United States. Its pipeline includes Renazorb, being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for the treatment of acute kidney injury. The company was incorporated in 2016 and is headquartered in Los Altos, California.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$106M
Employees
22
Headquarters
Los Altos, CA
Website
unicycive.com
CEO
Shalabh K. Gupta
Listed
July 12, 2021
P/E
-1.89
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
-$211,000
Operating income
-$30M
EBITDA
-$34.9M
Net income
-$39.9M
EPS
-$2.05
Total assets
$64.4M
Total debt
$815,000
Earnings yield
-52.84%

Price chart

3.134.596.057.508.96
UNCY 1D NASDAQ O3.95H4.02L3.71C3.89-0.06 (-1.40%)Vol512.91K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
UNCY Legal UNCY DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY Newsfile Corp
UNCY Legal What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline GuruFocus
UNCY Legal What's Next for Unicycive Therapeutics, Inc. Shareholders After 39.1% Stock Drop? Glancy Prongay Wolke & Rotter LLP Explains Securities Fraud Class Action Lead Plaintiff Deadline Glancy Prongay Wolke & Rotter LLP ("Glancy") announced today… PR Newswire
UNCY Legal UNCY Shareholder Alert: Unicycive Therapeutics, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky ACCESS Newswire
UNCY Legal UNCY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Unicycive Therapeutics (UNCY) Investors of Securities Class Action Lawsuit Deadline on November 2, 2026 Newsfile Corp
UNCY Legal Kaplan Fox Notifies Unicycive Therapeutics, Inc. (UNCY) Investors of a Pending Securities Class Action Deadline on November 2, 2026 Newsfile Corp
UNCY Legal UNCY DEADLINE NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - UNCY Newsfile Corp
UNCY Legal Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Urged to Join Class Action Before November 2, 2026 - Contact Levi & Korsinsky ACCESS Newswire
UNCY Legal UNCY DEADLINE FOR INVESTORS: Unicycive Therapeutics, Inc. Shareholders Encouraged to Contact Kirby McInerney LLP By November 2, 2026 Newsfile Corp
UNCY Legal Kaplan Fox Reminds Investors of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) to a Securities Class Action Deadline - Contact the Firm Before November 2, 2026 ACCESS Newswire
UNCY Legal What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline GuruFocus
UNCY Legal What Does Unicycive Therapeutics, Inc.'s 39.1% Stock Drop Mean for Investors? The Law Offices of Howard G. Smith Outlines Securities Fraud Class Action Lead Plaintiff Deadline The Law Offices of Howard G. PR Newswire
UNCY Legal Contact Levi & Korsinsky by November 2, 2026 to Join Class Action Against Unicycive Therapeutics, Inc. (UNCY) ACCESS Newswire
UNCY Legal UNCY UPCOMING DEADLINE: SueWallSt Alerts Unicycive Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm PRNewsWire
UNCY Legal Bronstein, Gewirtz & Grossman LLC Urges Unicycive Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm GlobeNewswire
UNCY Legal Lost Money on Unicycive Therapeutics, Inc. (UNCY)? Contact Levi & Korsinsky Before November 2, 2026 to Join Class Action ACCESS Newswire
UNCY Legal Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit GuruFocus
UNCY Legal Robbins LLP Reminds UNCY Investors of the Pending Lead Plaintiff Deadline in the Unicycive Therapeutics, Inc. Securities Class Action Lawsuit Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf… PR Newswire
UNCY Stock news Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027 GuruFocus
UNCY Legal Did You Lose Money on Unicycive Therapeutics, Inc. (UNCY)? Levi & Korsinsky Urges Investors to Act Before November 2, 2026 ACCESS Newswire
See more
FAQ

Questions about Unicycive Therapeutics, Inc.

What does Unicycive Therapeutics, Inc. do?
Unicycive Therapeutics, Inc. is a biotechnology company that develops novel therapies for kidney diseases in the United States. Its pipeline includes Renazorb, being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI 494, for the treatment of acute kidney injury. The company was incorporated in 2016 and is headquartered in Los Altos, California.
What is UNCY's market cap?
Unicycive Therapeutics, Inc. (UNCY) is a listed stock with a live quote. The latest market cap on this page is $106M.
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. is headquartered in Los Altos, CA.
How do I get UNCY news from the API?
Call GET /v1/news?tickers=UNCY. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search the full archive in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees the full archive.
How far back does UNCY news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for UNCY, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees the full archive as headlines are ingested. A Free API key returns the last year. Pro keys search the full archive.
Is the UNCY price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included. If you don't subscribe, the account stays on Free.

Start 7-day free trial Read the docs